• 1:中华预防医学会
• 2:中华预防医学会疫苗与免疫分会

摘要(Abstract)：

肺炎球菌性疾病是全球严重的公共卫生问题之一,也是导致中国儿童及成年人发病和死亡的重要原因。肺炎球菌性疾病的临床治疗用药以抗生素为主,由于抗生素的广泛应用,肺炎球菌的耐药性问题日益严重。采用肺炎球菌疫苗预防肺炎球菌性疾病并减少细菌耐药性,尤为必要和迫切。本文在《肺炎球菌性疾病免疫预防专家共识(2017版)》基础上,结合WHO肺炎球菌疫苗立场文件(2019年)和国内外最新研究进展,对肺炎球菌性疾病的病原学、临床学、流行病学、疾病负担、疫苗学等方面进行系统综述,目的是为公共卫生和预防接种专业人员在科学使用疫苗与发挥疫苗最佳预防作用方面提供证据,提高肺炎球菌性疾病防控水平。

关键词(KeyWords)： 肺炎球菌;肺炎球菌性疾病;肺炎球菌多糖结合疫苗;肺炎球菌多糖疫苗;免疫预防;共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author):

参考文献(References)：

• [1] WHO.Pneumococcal vaccines WHO position paper-2012[J].Weekly Epidemiology Record,2012,87(14):129-144.
• [2] WAHL B,O'BRIEN KL,GREENBAUM A,et al.Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines:global,regional,and national estimates for 2000-15[J].The Lancet Global Health,2018,6(7):744-757.
• [3] O'BRIEN KL,WOLFSON LJ,WATT JP,et al.Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years:global estimates[J].The Lancet,2009,374(9693):893-902.
• [4] 中华人民共和国卫生部.中国妇幼卫生事业发展报告(2011)[R].2011.
• [5] 孙谨芳,么鸿雁,于石成,等.1990年和2010年中国3种细菌性脑膜炎疾病负担情况[J].疾病监测,2015,30(12):1008-1013.
• [6] 黄广丽,石庆生,陈海霞,等.肺炎患儿咽部吸出物检测及细菌耐药性分析[J].河北医科大学学报,2016,37(1):40-43.
• [7] 刘又宁,陈民钧,赵铁梅,等.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8.
• [8] WHO.Meeting of the Immunization Strategic Advisory Group of Experts,November 2007--conclusions and recommendations[J].Weekly Epidemiology Record,2008,83(1):1-15.
• [9] PLOTKIN SA,ORENSTEIN WA,OFFIT PA.Vaccines[M].Sixth edition.Elsevier,2013:542.
• [10] PARK IH,PRITCHARD DG,CARTEE R,et al.Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae[J].Journal of Clinical Microbiology,2007,45(4):1225-1233.
• [11] PENNINGTON JE.Treating respiratory infections in the era of cost control[J].American Family Physician,1986,33(2):153-160.
• [12] 张雪梅.肺炎链球菌自然转化机制的研究进展[J].国外医学(临床生物化学与检验学分册),2002,23(6):348-350.
• [13] 孟江萍,尹一兵.肺炎链球菌致病机理的最新研究进展[J].微生物学杂志,2002,22(2):39-41.
• [14] 陈保德.肺炎链球菌致病的分子机理[J].国外医学临床生物化学与检验学分册,2002,23(6):362-364.
• [15] 黄彬,陈茶.肺炎链球菌蛋白质类的毒力因子[J].国外医学(临床生物化学与检验学分册),1999,20(2):71-73.
• [16] 鲜墨,吴忠道.肺炎链球菌感染的流行病学及毒力因子研究进展[J].热带医学杂志,2006,6(6):740-742+693.
• [17] MEERVELD-EGGINK A,WEERDT DO,VELZEN-BLAD VH,et al.Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients[J].Vaccine,2011,29(4):675-680.
• [18] HAUSDORFF WP,BRYANT J,PARADISO PR,et al.Which pneumococcal serogroups cause the most invasive disease:implications for conjugate vaccine formulation and use,part I[J].Clinical Infectious Diseases,2000,30(1):100-121.
• [19] ROMERO-STEINER S,LIBUTTI D,PAIS LB,et al.Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells[J].Clinical and Diagnostic Laboratory Immunology,1997,4(4):415-422.
• [20] WINKELSTEIN JA,SMITH MR,SHIN HS.The role of C3 as an opsonin in the early stages of infection 1[J].Proceedings of the Society for Experimental Biology and Medicine,2016,149(2):397-401.
• [21] ROMERO-STEINER S,FRASCH CE,CARLONE G,et al.Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines[J].Clinical and Vaccine Immunology ,2006,13(2):165-169.
• [22] 孟庆红,姚开虎.肺炎链球菌临床感染疾病谱[J].中华全科医学,2018,16(9):1535-1539+1544.
• [23] 周凯,韩青.儿童少见肺炎链球菌病的临床特征[J].中华实用儿科临床杂志,2019,34(22):1685-1686+1689.
• [24] 姚开虎,赵顺英,杨永弘.儿童肺炎链球菌坏死性肺炎[J].中国循证儿科杂志,2007,2(6):449-454.
• [25] 王玉静,刘春峰.儿童肺炎链球菌坏死性肺炎临床特点分析[J].中国小儿急救医学,2017,24(1):50-55.
• [26] 张园园,戴菱蔓,周云连,等.儿童细菌性坏死性肺炎与肺炎支原体坏死性肺炎临床特征及预后比较[J].中华儿科杂志,2019,57(8):625-626+630.
• [27] MOORE DP,DAGAN R,MADHI SA.Respiratory viral and pneumococcal coinfection of the respiratory tract:implications of pneumococcal vaccination[J].Expert Review of Respiratory Medicine,2012,6(4):451-465.
• [28] ZHU X,GE Y,WU T,et al.Co-infection with respiratory pathogens among COVID-2019 cases[J].Virus Research,2020,285:198005.
• [29] 朱亮,李文辉,王新红,等.2012至2017年1138例儿童侵袭性肺炎链球菌病多中心临床研究[J].中华儿科杂志,2018,56(12):915-922.
• [30] 俞桑洁,王辉,沈叙庄,等.肺炎链球菌临床检验规程的共识[J].中华检验医学杂志,2012,35(12):1066-1072.
• [31] 李昌崇,尚云晓,沈叙庄,等.儿童社区获得性肺炎管理指南(2013修订)(上)[J].中华儿科杂志,2013,51(10):745-752.
• [32] 中华医学会儿科分会感染学组,《中华儿科杂志》编辑委员会.中国儿童肺炎链球菌性疾病的诊疗与防控建议[J].中华儿科杂志,2018,56(8):564-570.
• [33] LYU S,YAO KH,DONG F,et al.Vaccine serotypes of Streptococcus pneumoniae with high-level antibiotic resistance isolated more frequently seven years after the licensure of PCV7 in Beijing[J].The Pediatric Infectious Disease Journal,2016,35(3):316-321.
• [34] SONG JH.Advances in pneumococcal antibiotic resistance[J].Expert Review of Respiratory Medicine,2013,7(5):491-498.
• [35] WHO.Pneumococcal conjugate vaccines in infants and children under 5 years of age:WHO position paper-February 2019.[J].Weekly Epidemiological Record,2019,94(8):85-104.
• [36] 姚开虎,王立波,赵根明,等.四家儿童医院住院肺炎病例肺炎链球菌分离株的耐药性监测[J].中国当代儿科杂志,2008,10(3):275-279.
• [37] 王利民,吴俊琪,方寅飞.学龄前儿童下呼吸道感染肺炎链球菌的流行病学特征与耐药性变迁[J].中国卫生检验杂志,2016,26(9):1349-1352.
• [38] CaLSI.Performance standards for antimicrobial susceptibility testing:twenty-eighth informational supplement M100-S28[S].Wayne,PA,USA,2018.
• [39] 胡付品,郭燕,朱德妹,等.2017年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2018,18(3):241-251.
• [40] MEN WD,DONG QL,SHI W,et al.Serotype distribution and antimicrobial resistance patterns of invasive pneumococcal disease isolates from children in mainland China—a systematic review[J].Brazilian Journal of Microbiology,2020,51(47):665-672.
• [41] SHI W,LI J,DONG F,et al.Serotype distribution,antibiotic resistance pattern,and multilocus sequence types of invasive Streptococcus pneumoniae isolates in two tertiary pediatric hospitals in Beijing prior to PCV13 availability[J].Expert Review of Vaccines,2019,18(1):89-94.
• [42] KIM SH,SONG JH,CHUNG DR,et al.Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries:an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study[J].Antimicrobial Agents and Chemotherapy,2012,56(3):1418-1426.
• [43] WHO.Pneumococcal conjugate vaccine for childhood immunization--WHO position paper[J].Weekly Epidemiology Record,2007,82(12):93-104.
• [44] YAO KH,YANG YH.Streptococcus pneumoniae diseases in Chinese children:past,present and future[J].Vaccine,2008,26(35):4425-4433.
• [45] CAI K,WANG YZ,GUO ZQ,et al.Clinical characteristics and antimicrobial resistance of pneumococcal isolates of pediatric invasive pneumococcal disease in China[J].Infection and Drug Resistance,2018,11:2461-2469.
• [46] MAHON BE,EHRENSTEIN V,NORGAARD M,et al.Perinatal risk factors for hospitalization for pneumococcal disease in childhood:a population-based cohort study[J].Pediatrics,2007,119(4):804-812.
• [47] ACIP.Preventing pneumococcal disease among infants and young children.Recommendations of the Advisory Committee on Immunization Practices (ACIP)[J].MMWR Recommendations and Reports,2000,49(RR-9):1-35.
• [48] BURGOS J,LARROSA MN,MARTINEZ A,et al.Impact of influenza season and environmental factors on the clinical presentation and outcome of invasive pneumococcal disease[J].European Journal of Clinical Microbiology & Infectious Diseases,2015,34(1):177-186.
• [49] INMACULADA P,JAVIER DD,LEOPOLDO S,et al.Risk factors for invasive disease among children in Spain[J].The Journal of Infection,2004,48(4):320-329.
• [50] KADIOGLU A,WEISER JN,PATON JC,et al.The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease[J].Nature Reviews Microbiology,2008,6(4):288-301.
• [51] ROY S,KNOX K,SEGAL S,et al.MBL genotype and risk of invasive pneumococcal disease:a case-control study[J].The Lancet,2002,359(9317):1569-1573.
• [52] MANDELL LA,WUNDERINK RG,ANZUETO A,et al.Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults[J].Clinical Infectious Diseases,2007,44(Suppl 2):27-72.
• [53] CDC.Prevention of pneumococcal disease:recommendations of the Advisory Committee on Immunization Practices (ACIP)[J].MMWR Recommendations and Reports,1997,46(RR-8):1-24.
• [54] European CDC.Use of pneumococcal polysaccharide vaccine for subjects over 65 years of age during an inter-pandemic period Stockholm,January 2007.Techinal Report of the scientific panel on vaccines and immunization[EB/OL].(2006-01-18) [2020-05-11].https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0701_TER_Use_of_pneumococcal_polysaccharide_vaccine.pdf.
• [55] FEIKIN DR,FELDMAN C,SCHUCHAT A,et al.Global strategies to prevent bacterial pneumonia in adults with HIV disease[J].The Lancet Infectious Diseases,2004,4(7):445-455.
• [56] CDC.Recommended Adult Immunization Schedule- United States,October 2006--September 2007[J/OL].Morbidity and Mortality Weekly Report,2006,55:Q1-Q4.(2006-10-13) [2020-05-11].https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5540a10.htm.
• [57] ROBINSON KA,BAUGHMAN W,ROTHROCK G,et al.Epidemiology of invasive Streptococcus pneumoniae infections in the United States,1995-1998:opportunities for prevention in the conjugate vaccine era[J].The Journal of the American Medical Association,2001,285(13):1729-1735.
• [58] NUORTI JP,BUTLER JC,FARLEY MM,et al.Cigarette smoking and invasive pneumococcal disease.Active Bacterial Core Surveillance Team[J].The New England Journal of Medicine,2000,342(10):681-689.
• [59] BENDER JM,AMPOFO K,KORGENSKI K,et al.Pneumococcal necrotizing pneumonia in Utah:does serotype matter?[J].Clinical Infectious Diseases,2008,46(9):1346-1352.
• [60] THOMAS RT,TINA VH,ED M,et al.Asthma as a risk factor for invasive pneumococcal disease[J].The New England Journal of Medicine,2005,352(20):2082-2090.
• [61] SANJAY S,TIMOTHY FM.Infection in the pathogenesis and course of chronic obstructive pulmonary disease[J].The New England Journal of Medicine,2008,359(22):2355-2365.
• [62] MORENS DM,TAUBENBERGER JK,FAUCI AS.Predominant role of bacterial pneumonia as a cause of death in pandemic influenza:implications for pandemic influenza preparedness[J].The Journal of Infectious Diseases,2008,198(7):962-970.
• [63] CDC.Vaccine preventable deaths and the Global Immunization Vision and Strategy,2006-2015[J].Morbidity and Mortality Weekly Report,2006,55(18):511-515.
• [64] WHO.Estimated Hib and pneumococcal deaths for children under 5 years of age,2008[R].Geneva:WHO,2013.
• [65] ROTH GA,ABATE D,ABATE KK,et al.Global,regional,and national age-sex-specific mortality for 282 causes of death in 195 countries and territories,1980-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].The Lancet,2018,392(10159):1736-1788.
• [66] ACoI.Preventing pneumococcal disease among infants and young children:recommendations of the Advisory Committee on Immunization Practices (ACIP)[J].MMWR Recommendations and Reports,2000,49(RR-9):1-35.
• [67] CDC.Active Bacterial Core surveillance Report (ABCs),Emerging Infections Program Network,Streptococcus pneumoniae,2010[EB/OL].(2012-04-06)[2020-05-17].http://www.cdc.gov/abcs/reports-findings/survreports/spneu10.html.
• [68] CDC.Active Bacterial Core surveillance Report (ABCs),Emerging Infections Program Network,Streptococcus pneumoniae,2013[EB/OL].(2015-05-18)[2020-05-17].http://www.cdc.gov/abcs/reports-findings/survreports/spneu13.html.
• [69] DONKOR ES,ANNAN JA,BADOE EV,et al.Pneumococcal carriage among HIV infected children in Accra,Ghana[J].BMC Infectious Diseases,2017,17(1):133.
• [70] BEREZIN EN,IAZZETTI MA.Evaluation of the incidence of occult bacteremia among children with fever of unknown origin[J].Brazilian Journal of Infectious Diseases,2017,10(6):396-399.
• [71] AVNER JR,BAKER MD.Occult bacteremia in the post-pneumococcal conjugate vaccine era:does the blood culture stop here?[J].Academic Emergency Medicine :Official Journal of the Society for Academic Emergency Medicine,2009,16(3):258-260.
• [72] ALPERN ER,ALESSANDRINI EA,BELL LM,et al.Occult bacteremia from a pediatric emergency department:current prevalence,time to detection,and outcome[J].Pediatrics,2000,106(3):505-511.
• [73] CDC.Epidemiology and prevention of vaccine-preventable diseases-pneumococcal disease[EB/OL].(2019-04-15) [2020-05-17].http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.
• [74] BJORNSON G,SCHEIFELE D,BINDER F,et al.Population-based incidence rate of invasive pneumococcal infection in children:Vancouver,1994-1998[J].Canada Communicable Disease Report,2000,26(18):149-151+152.
• [75] ESKOLA J,TAKALA AK,KELA E,et al.Epidemiology of invasive pneumococcal infections in children in Finland[J].The Journal of the American Medical Association,1992,268(23):3323-3327.
• [76] VON KRIES R,SIEDLER A,SCHMITT HJ,et al.Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines[J].Clinical Infectious Diseases,2000,31(2):482-487.
• [77] KYU HH,ABATE D,ABATE KH,et al.Global,regional,and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories,1990-2017:a systematic analysis for the global burden of disease study 2017[J].The Lancet,2018,392(10159):1859-1922.
• [78] WHO.Global health estimates 2015 summary tables:global DALYs by cause,age and sex,2000-2015[EB/OL].(2016-12) [2020-05-17].http://www.who.int/entity/healthinfo/global_burden_disease/GHE2015_DALY_Global_2000_2015.xls?ua=1.
• [79] KASSEBAUM NJ,ARORA M,BARBER RM,et al.Global,regional,and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE),1990-2015:a systematic analysis for the global burden of disease study 2015[J].The Lancet,2016,388(10053):1603-1658.
• [80] MURRAY JLC,VOS T,LOZANO R,et al.Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions,1990-2010:a systematic analysis for the Global Burden of Disease Study 2010[J].The Lancet,2012,380(9859):2197-2223.
• [81] WEYCKER D,STRUTTON D,EDELSBERG J,et al.Clinical and economic burden of pneumococcal disease in older US adults[J].Vaccine,2010,28(31):4955-4960.
• [82] GENEVIèVE P,PHILIPPE DE,BARBARA L,et al.Epidemiological and economic burden of pneumococcal diseases in Canadian children[J].Canadian Journal of Infectious Diseases,2003,14(4):215-220.
• [83] EARLE K,WILLIAMS S.Burden of pneumococcal disease in adults aged 65 years and older:an Australian perspective[J].Pneumonia,2016,8(1):9.
• [84] CHEN Y,DENG W,WANG SM,et al.Burden of pneumonia and meningitis caused by Streptococcus pneumonia in China among children under 5 years of age:a systematic literature review[J].PLos One,2011,6(11):e27333.
• [85] NAGHAVI M,ABAJOBIR AA,ABBAFATI C,et al.Global,regional,and national age-sex specific mortality for 264 causes of death,1980-2016:a systematic analysis for the Global Burden of Disease Study 2016[J].The Lancet,2017,390(10100):1151-1210.
• [86] 国家卫生健康委员会.2018中国卫生健康统计年鉴[M].北京:中国协和医科大学出版社,2018.
• [87] 宁桂军,王旭霞,刘世文,等.2015-2016年甘肃省白银市5岁以下儿童社区获得性肺炎疾病负担回顾性调查[J].中国疫苗和免疫,2017,23(1):18-21+12.
• [88] NING GJ,WANG XX,WU D,et al.The etiology of community-acquired pneumonia among children under 5 years of age in mainland China,2001-2015:a systematic review[J].Human Vaccines & Immunotherapeutics,2017,13(11):2742-2750.
• [89] TAO LL,HU BJ,HE LX,et al.Etiology and antimicrobial resistance of community-acquired pneumonia in adult patients in China[J].Chinese Medical Journal,2012,125(17):2967-2972.
• [90] HUANG HH,ZHANG YY,XIU QY,et al.Community-acquired pneumonia in Shanghai,China:microbial etiology and implications for empirical therapy in a prospective study of 389 patients[J].European Journal of Clinical Microbiology & Infectious Diseases,2006,25(6):369-374.
• [91] HU JY,SUN XD,HUANG ZY,et al.Streptococcus pneumoniae and Haemophilus influenzae type b carriage in Chinese children aged 12-18 months in Shanghai,China:a cross-sectional study[J].BMC Infectious Diseases,2016,16:149.
• [92] ZHOU M,WANG H,ZHU J,et al.Cause-specific mortality for 240 causes in China during 1990-2013:a systematic subnational analysis for the global burden of disease study 2013[J].The Lancet,2016,387(10015):251-272.
• [93] LIMCANGCO MRT,SALOLE EG,ARMOUR CL.Epidemiology of Haemophilus influenzae type b meningitis in Manila,Philippines,1994 to 1996[J].The Pediatric Infectious Disease Journal,2000,19(1):7-11.
• [94] MAHMOUD R,MAHMOUD M,BADRINATH P,et al.Pattern of meningitis in Al-Ain medical district,United Arab Emirates—a decadal experience (1990-99)[J].Journal of Infection,2002,44(1):22-25.
• [95] HUSSAIN HMII,SOFIAH LIA,ONG CL,et al.Haemophilus influenzae meningitis in Malaysia[J].The Pediatric Infectious Disease Journal,1998,17(Suppl 9):189-190.
• [96] TAYLOR HG,MICHAELS RH,MAZUR PM,et al.Intellectual,neuropsychological,and achievement outcomes in children six to eight years after recovery from Haemophilus influenzae meningitis[J].Pediatrics,1984,74(2):198-205.
• [97] 卫生福利部统计处.全民健康保险医疗统计[EB/OL].2017.[2020-05-11].http://www.mohw.gov.tw/CHT/DOS/Statistic.aspx?f_list_no=312&fod_list_no=1604.
• [98] 卫生福利部统计处.死因统计[EB/OL].2017.[2020-05-11].http://www.mohw.gov.tw/CHT/DOS/Statistic.aspx?f_list_no=312&fod_list_no=1610.
• [99] TING YT,LU CY,SHAO PL,et al.Epidemiology of community-acquired bacteremia among infants in a medical center in Taiwan,2002-2011[J].Journal of Microbiology,Immunology and Infection,2015,48(4):413-418.
• [100] 王进东,张再兴,孙静涛,等.唐山地区2008～2013年儿童急性中耳炎流行病学调查[J].中国妇幼保健,2015,30(6):939-941.
• [101] 刘俊英,赵英,张爱凤,等.唐山地区儿童急性中耳炎常见病原菌及药物敏感性分析[J].现代预防医学,2014,41(19):3517-3519+3529.
• [102] 景阳,韩想利,王宇娟,等.西安地区290例儿童急性中耳炎分泌物细菌培养及药敏分析[J].检验医学与临床,2016,13(4):457-459.
• [103] Institute for Health Metrics and Evaluation.Global health data exchange[EB/OL].(2019-03-30) [2020-05-17].http://ghdx.healthdata.org/gbd-2016.
• [104] LI Y,AN Z,YIN D,et al.Disease burden of community acquired pneumonia among children under 5 y old in China:a population based survey[J].Human Vaccines & Immunotherapeutics,2017,13(7):1681-1687.
• [105] 周勇,陈泽玲,王缃赟.珠海市社区获得性肺炎疾病负担研究[J].深圳中西医结合杂志,2016,26(20):81-82.
• [106] 邸明芝,曹迎,黄辉,等.248例成人社区获得性肺炎病例疾病负担调查[J].现代预防医学,2014,41(14):2560-2562+2584.
• [107] 宋圣帆.肺炎链球菌疾病费用研究与七价肺炎球菌结合疫苗的卫生经济学评价[D].上海:复旦大学,2013.
• [108] 朱琳,刘国恩,李冬美,等.儿童七价肺炎球菌结合疫苗的成本效果分析[J].中国卫生经济,2013,32(4):71-75.
• [109] 王婧,黄卓英,胡家瑜,等.上海市某社区5 岁以下儿童肺炎发病与诊疗情况分析[J].上海预防医学,2018,30(7):552-556.
• [110] 刘文婷.部分地区三种主要细菌性脑膜炎病例经济负担调查[D].北京:中国疾病预防控制中心,2016.
• [111] WU DB,ROBERTS CS,HUANG YC,et al.A retrospective study to assess the epidemiological and economic burden of pneumococcal diseases in adults aged 50 years and older in Taiwan[J].Journal of Medical Economics,2014,17(5):312-319.
• [112] JOHNSON HL,DELORIA-KNOLL M,LEVINE OS,et al.Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five:the pneumococcal global serotype project[J].PLoS Medicine,2010,7(10):e1000348.
• [113] PILISHVILI T,LEXAU C,FARLEY MM,et al.Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine[J].The Journal of Infectious Diseases,2010,201(1):32-41.
• [114] KAPLAN SL,BARSON WJ,LIN PL,et al.Serotype 19A is the most common serotype causing invasive pneumococcal infections in children[J].Pediatrics,2010,125(3):429-436.
• [115] KAPLAN SL,BARSON WJ,LIN PL,et al.Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine[J].The Pediatric Infectious Disease Journal,2013,32(3):203-207.
• [116] IROH TAM PY,THIELEN BK,OBARO SK,et al.Childhood pneumococcal disease in Africa - a systematic review and meta-analysis of incidence,serotype distribution,and antimicrobial susceptibility[J].Vaccine,2017,35(15):1817-1827.
• [117] FOSTER D,KNOX K,WALKER AS,et al.Invasive pneumococcal disease:epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region,England[J].Journal of Medical Microbiology,2008,57(4):480-487.
• [118] MOTLOVA J,BENES C,KRIZ P.Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines,1997-2006[J].Epidemiology and Infection,2009,137(4):562-569.
• [119] GONZáLEZ-DíAZ A,CAMARA J,ERCIBENGOA M,et al.Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain[J].Clinical Microbiology and Infection,2020,26(6):753-759.
• [120] GUILLERMO L,SELENE GG,MIGUEL L,et al.Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016):surveillance data from 23 sites in Catalonia,Spain[J].PLoS One,2020,15(2):e0228612.
• [121] WOUTERS I,DESMET S,VAN HEIRSTRAETEN L,e